Cases report of unicentric castleman's disease: Revisit of radiotherapy role

Radiation Oncology Journal

Volumn 31, Issue 1, 2013, Pages 48-54

  Kyu Noh, O ^a   Lee, Sang Wook ^b   Lee, Jae Whan ^b   Kim, Sang Yoon ^b   Kim, Chung Soo ^b   Choi, Eun Kyung ^b   Kim, Jong Hoon ^b   Ahn, Seung Do ^b  

^a Ajou University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Castleman's disease; Hyaline vascular; Radiotherapy

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; FLUORODEOXYGLUCOSE F 18;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENOPATHY; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE;

EID: 84876484179     PISSN: 22341900     EISSN: 22343164     Source Type: Journal    
DOI: 10.3857/roj.2013.31.1.48     Document Type: Article

References (20)

1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9:822-30.
2. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95:1406-12.
3. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972;29:670-83.
4. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999;85:706-17.
5. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978;69:86-90.
6. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001;92:670-6.
7. Nordstrom DG, Tewfik HH, Latourette HB. Giant lymph node hyperplasia: a review of literature and report of two cases of plasma cell variant responding to radiation therapy. Int J Radiat Oncol Biol Phys 1978;4:1045-8.
8. Fitzpatrick PJ, Brown TC. Angiofollicular lymph node hyperplasia. Can Med Assoc J 1968;99:1259-62.
9. Weisenburger DD, DeGowin RL, Gibson P, Armitage JO. Remission of giant lymph node hyperplasia with anemia after radiotherapy. Cancer 1979;44:457-62.
10. Marti S, Pahissa A, Guardia J, Moragas A, Bacardi R. Multicentric giant follicular lymph node hyperplasia: favorable response to radiotherapy. Cancer 1983;51:808-10.
11. Stokes SH, Griffith RC, Thomas PR. Angiofollicular lymph node hyperplasia (Castleman's disease) associated with vertebral destruction. Cancer 1985;56:876-9.
12. Sethi T, Joshi K, Sharma SC, Gupta BD. Radiation therapy in the management of giant lymph node hyperplasia. Br J Radiol 1990;63:648-50.
13. Massey GV, Kornstein MJ, Wahl D, Huang XL, McCrady CW, Carchman RA. Angiofollicular lymph node hyperplasia (Castleman's disease) in an adolescent female: clinical and immunologic findings. Cancer 1991;68:1365-72.
14. Veldhuis GJ, Van Der Leest AH, De Wolf JT, De Vries EG, Vellenga E. A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspects. Ann Hematol 1996;73:47-50.
15. Neuhof D, Debus J. Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol 2006;45:1126-31.
16. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985;3:1202-16.
17. Repetto L, Jaiprakash MP, Selby PJ, Gusterson BA, Williams HJ, McElwain TJ. Aggressive angiofollicular lymph node hyperplasia (Castleman's disease) treated with high dose melphalan and autologous bone marrow transplantation. Hematol Oncol 1986;4:213-7.
18. Andres E, Maloisel F. Interferon-alpha as first-line therapy for treatment of multicentric Castleman's disease. Ann Oncol 2000;11:1613-4.
19. Rieu P, Droz D, Gessain A, Grunfeld JP, Hermine O. Retinoic acid for treatment of multicentric Castleman's disease. Lancet 1999;354:1262-3.
20. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.